Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study
Authors' conclusion
Real-world data suggest that oral semaglutide is an effective and safe alternative to sulfonylureas for T2DM patients, with no reported hypoglycaemic episodes.
Study context
- Population
- People with T2D switching from SU to daily oral semaglutide; mean age 68.9 ± 9.9 years
- Participants
- 104 people
- Exposure
- Oral semaglutide after suspending or reducing SU
- Outcome
- Change in HbA1c from baseline
- Follow-up
- Average 37 weeks
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
HbA1c, baseline to follow-up
- HbA1c decreased from baseline to follow-up
- 7.62% to 7.42%
- Mean HbA1c reduction
- 0.22%
- P value
- p = 0.04
Observational data: associations, not effects.
Secondary outcomes
Proportion achieving HbA1c ≤7%
- Increased from baseline to follow-up
- 29.8% to 36.3%
Body weight
- Significant reduction
- 3.03 kg
- P value
- P < 0.001
Fasting blood sugar, waist circumference, diastolic blood pressure, total cholesterol, albumin-to-creatinine ratio
- Significant reductions
- P < 0.05
HDL-C and eGFR
- HDL-C and eGFR increased
10-year cardiovascular risk score
- Decreased from baseline to follow-up
- 17.0% to 12.9%
- P value
- P < 0.001
Safety
Treatment discontinuation, adverse events and hypoglycaemia
- Treatment discontinuation
- 9.6%
- Adverse events, primarily gastrointestinal
- 12.5%
- Hypoglycaemic events
- 0
Original publication
Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study. Diabetes Obes Metab. Published 6 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →